Phospholipid-bound beta 2-glycoprotein I induces the production of anti-phospholipid antibodies.
Apoptotic-cell-bound beta2-glycoprotein I (beta2GPI), but not apoptotic cells or beta2GPI alone, can induce the production of anti-phospholipid (anti-PL) antibodies (Ab) in normal mice. Although it is presumed that beta2GPI binds to anionic phospholipid (PL) exposed on the apoptotic cell membrane, the precise nature of this complex and its immunogenicity is unclear. To address these issues, we investigated the structure and immunogenicity of human beta2GPI in the presence of different PL that may be expressed on the surface of apoptotic cells. BALB/c mice were immunized intravenously (iv) with beta2GPI in the presence of cardiolipin (CL), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylcholine (PC), or PS/PC (25%/75%) vesicles. Cardiolipin+beta2GPI induced the highest levels of anti-beta2GPI and anti-CL IgG Ab and lupus anticoagulant (LA) activity, while beta2GPI with PC or PS/PC vesicles produced no significant anti-PL Ab. PS+beta2GPI was somewhat immunogenic, but less so than PG+beta2GPI. beta2GPI was immunogenic in the presence of native (CL(N)), but not hydrogenated (CL(H)), CL. Circular dichroism analysis demonstrated that the structure of beta2GPI was altered specifically by interaction with CL(N), but not other anionic PL, including CL(H). Similarly, the structure of CL(N)was affected by interaction with beta2GPI, as detected by(31)P nuclear magnetic resonance. These findings demonstrate that beta2GPI complexed with CL(N)is structurally altered, highly immunogenic, and induces the production of IgG anti-PL Ab. Furthermore, the structural modification and the generation of immunogenic epitopes on beta2GPI upon interaction with CL(N)require the presence of unsaturated fatty acid chains, suggesting a role for oxidation in this process.
Division of Rheumatology, Department of Medicine, The Montreal General Hospital Research Institute, McGill University, Montreal, QC, H3G 1A4, Canada.
R
R
Subang
J S
JS
Levine
A S
AS
Janoff
S M
SM
Davidson
T F
TF
Taraschi
T
T
Koike
S R
SR
Minchey
M
M
Whiteside
M
M
Tannenbaum
J
J
Rauch
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000096:biosynthesis*; D017209:Apoptosis / Q000276:immunology; D002308:Cardiolipins / Q000008:administration & dosage / Q000276:immunology; D002942:Circular Dichroism; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000145:classification; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D019906:Nuclear Magnetic Resonance, Biomolecular; D010743:Phospholipids / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism*; D053482:beta 2-Glycoprotein I
D000276:Adjuvants, Immunologic; D017152:Antibodies, Antiphospholipid; D002308:Cardiolipins; D006023:Glycoproteins; D007074:Immunoglobulin G; D046911:Macromolecular Substances; D008562:Membrane Glycoproteins; D010743:Phospholipids; D053482:beta 2-Glycoprotein I